Spondyloarthritis & psoriatic arthritis
Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry
Authors' conclusion
In this national multicenter registry, female sex was associated with less response to a first-line TNFi by the second year of follow-up. A higher age at the start of the TNFi was the main factor associated with an unfavorable response to TNFi.
Study context
- Population
- Patients with axial spondyloarthritis (SpA) enrolled in the BIOBADASER registry (2000–2019) who initiated a tumor necrosis factor inhibitors (TNFi) (first, second, or further lines)
- Participants
- 969 patients
- Exposure
- Females vs males initiating a TNFi
- Femalesn = 315
- Malesn = 654reference
- Outcome
- Response to TNFi: BASDAI50 (improvement of at least 50% of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score) and ASDAS-CRP
Methodological detailsnational, multicentre, statistical and artificial intelligence (AI)-based data analyses, logistic regression
- National
- Multicentre
- Statistical and AI-based data analyses
- Logistic regression
Main finding
As reported in the abstract
BASDAI50 response with first-line TNFi · second year of follow-up
- Females had a lesser reduction of the ASDAS-CRP at the second year
- Females vs Males: P = 0.018
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| BASDAI50 response to TNFi (logistic regression model)Lower BASDAI50 responses in females | P = 0.05 |
Older age and unfavorable response to TNFi
- Older age associated with unfavorable responses
- P = 0.004
AI data analyses
- Age at start of treatment was the main factor associated with an unfavorable response
- Age combined with female sex or cardiovascular risk factors and events potentially contributed to an unfavorable response to TNFi
Original publication
Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry. Arthritis Care Res (Hoboken). Published 9 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →